
Dr Gareth Jones
BSc, 1st class Hons, PhD
Expertise
My research investigates how cytokines regulate immune cells to influence pathological outcomes in chronic inflammatory diseases and how we can target these responses to develop novel treatment approaches.
Current positions
Senior Lecturer
School of Cellular and Molecular Medicine
Contact
Press and media
Many of our academics speak to the media as experts in their field of research. If you are a journalist, please contact the University’s Media and PR Team:
Biography
After completing my PhD in Biochemistry, I joined Professor Simon Jones’ laboratory at the School of Medicine, Cardiff University. In 2010, I secured an Arthritis Research UK Travelling Fellowship and moved to the Monash (now Hudson) Institute of Medical Research in Melbourne where I worked with Professor Brendan Jenkins. I later returned to Cardiff University and was awarded a Versus Arthritis Career Development Fellowship in 2013. In 2019 I moved to the School of Cellular and Molecular Medicine at The University of Bristol as a Senior Lecturer in Immunology.
My group is interested in understanding the mechanisms underpinning chronic inflammation and tissue damage. We examine how cytokines regulate the development, effector function and maintenance of immune cells within inflamed tissues, with a particular interest in the negative regulation of inflammation to restore tissue homeostasis. Our research is geared towards identifying novel therapeutic targets and biomarkers of inflammatory arthritis pathology, thus linking basic mechanistic understanding with translational outcomes.
Research interests
Inflammation and Cytokines Laboratory
The Jones laboratory investigates cytokine-regulated mechanisms that underpin chronic inflammation and immune-mediated tissue damage.
Vision
Inflammation is the body’s natural response to infection and tissue injury. Cytokines orchestrate all aspects of the inflammatory response including immune cell activation, migration, survival and effector function. Optimal control of this process ensures competent host defence. However, persistent or non-resolving episodes of inflammation often leads to tissue damage.
Our research examines how cytokines regulate the development, organisation, effector characteristics and maintenance of immune cells within inflamed tissues, with a particular interest in the negative regulation of inflammation to restore immune and tissue homeostasis.
With a primary focus in inflammatory arthritis, our research aims to exploit cytokines therapeutically and to define cytokine signatures that reflect patient outcomes.
Mission
Our ultimate goal is to aid clinical decision-making through identifying diagnostic markers and novel therapies that can inform patient stratification and treatment.
Approach
Spanning basic, pre-clinical and early clinical studies, we are investigating novel drugs for the treatment for inflammatory diseases and cytokine signatures that reflect disease activity. We combine cell culture, in vivo disease models, analysis of clinical samples and ‘big data’ approaches (e.g., RNA-sequencing), thus linking basic mechanistic studies with translational outcomes.
A particular area of focus is the mechanisms that govern the development, organisation and activity of lymph node-like compartments (called ectopic lymphoid structures; ELS) that develop within chronically inflamed tissues. Our research considers cross-disease and disease-specific mechanisms that regulate ELS across autoimmunity, infection and cancer. Here, we propose that immunomodulation of cytokine networks holds real potential for the treatment of chronic diseases where ELS feature.
Projects and supervisions
Research projects
Targeting cellular metabolism to treat Th17-driven pathology
Principal Investigator
Managing organisational unit
School of Cellular and Molecular MedicineDates
18/09/2024 to 17/09/2026
Galectin-3 as a determinant of T cell-driven pathology: targeting galectin-3 to restore tissue integrity in uveitis and arthritis-associated uveitis.
Principal Investigator
Managing organisational unit
School of Cellular and Molecular MedicineDates
01/06/2024 to 31/05/2027
Galectin-3 as a determinant of T cell-driven pathology: targeting galectin-3 to restore tissue integrity in uveitis and arthritis-associated uveitis.
Principal Investigator
Managing organisational unit
School of Cellular and Molecular MedicineDates
01/06/2024 to 31/05/2027
Protein tyrosine phosphatases as rheostats of Jak-STAT cytokine signals and determinants of disease heterogeneity
Principal Investigator
Managing organisational unit
School of Cellular and Molecular MedicineDates
15/11/2022 to 14/11/2025
A mechanistic evaluation of gliflozins in CD4+ T cells and their repurposing in T cell-mediated autoimmunity
Principal Investigator
Managing organisational unit
School of Cellular and Molecular MedicineDates
01/10/2022 to 30/09/2025
Publications
Recent publications
01/01/2025Transcriptome-wide Mendelian randomisation exploring dynamic CD4+ T cell gene expression in colorectal cancer development
Transcriptome-wide Mendelian randomisation exploring dynamic CD4+ T cell gene expression in colorectal cancer development
IL-27 maintains cytotoxic Ly6C+ γδ T cells that arise from immature precursors
EMBO Journal
Th17-to-Tfh plasticity during periodontitis limits disease pathology
Journal of Experimental Medicine
Tracking Cardiovascular Comorbidity in Models of Chronic Inflammatory Disease
Inflammation and Cancer
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity
Cell Metabolism